home > news > detailed info

Juvisé Pharmaceuticals Successfully Complete a €400M Refinancing Following the Acquisition of the Worldwide Rights of Pylera

Juvisé Pharmaceuticals

Paris, France, July 5, 2022
: The French speciality pharmaceutical company, Juvisé Pharmaceuticals has recently completed a transaction with AbbVie, regarding the acquisition of the worldwide commercial rights of Pylera®. Details of this transaction remain undisclosed.

A €400 million financing was raised with Société Générale, Juvisé Pharmaceuticals historic and lead bank, supporting the funding of this latest acquisition together with the refinancing of its existing debt. Lazard and Latham & Watkins served as financial and legal advisors for Juvisé Pharmaceuticals, whereas White & Case served as legal advisors for Société Générale.

Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared « We are delighted to have successfully accomplished this transaction with AbbVie regarding Pylera®, a high-quality medicine, crucial for patients suffering from a serious gastro-intestinal disease. We were also pleased to be able to count on the permanent and unwavering support of our long-term banking partner, Société Générale.

This is another example of Juvisé Pharmaceuticals capacity to establish successful alliances with world class pharmaceuticals actors as per previous transactions concluded with Novartis and AstraZeneca. This acquisition also highlights Juvisé Pharmaceuticals strengths in deal selection and transaction execution.

About Pylera®

Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease. The eradication of the pathogen agent has been shown to reduce the risk of peptic ulcers recurrence and gastric cancers.
phone +33 (0)4 26 29 40 00
email 28 rue Bayard 75008 Paris
Print this page
Send to a friend
News and Press Releases

European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants

Paris, November 4, 2022. The European Commission has approved Beyfortus® (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two. Beyfortus is the first and only single-dose RSV protective option for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. Beyfortus is being developed jointly by Sanofi and AstraZeneca.
More info >>

White Papers

What You Need To Know About Thermal Shipping Technologies

Temptime Corporation

This paper presents highlights from a thermal performance study conducted by Modality Solutions LLC. The study examined the performance of five shipping technologies commonly used by specialty pharmacies to transport high-value refrigerated specialty medicines against an industry accepted temperature profile standard.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement